REVIEW PAPER
The treatment of polymyositis, dermatomyositis and inclusion body myositis
Online publication date: 2010-07-02
Reumatologia 2010;48(3):188-193
KEYWORDS
ABSTRACT
Idiopathic inflammatory myopathy is a group of diseases of unknown etiology and probably autoimmune pathogenesis. Treatment of the diseases is divided into following stages: initial phase, intermediate phase, and long-lasting therapy. Glicocorticoids and other immunosuppressive drugs (commonly azathioprine and methotrexate) are applied for management. It is important to evaluate activity of the disease, effectiveness of the treatment and occurrence of adverse reactions. Inclusion body myositis is resistant to glicocorticoid therapy.
REFERENCES (23)
1.
Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991; 325: 1487-1498. .
2.
Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-982. .
3.
Lundberg IE, Vencovsky J, Dani L. Polymyositis, dermatomyositis, inflammatory diseases of muscles and other myopathies. In: EULAR Compendium. Bijlsma JW, et al. (eds). BMJ, London 2009; 297-313. .
4.
Kucharz EJ. Idiopatyczna miopatia zapalna. W: Reumatologia. Interna. Puszczewicz M (red.) – w druku. .
5.
Isenberg DA, Allen E, Farewell V, et al. International Myositis and Clinical Studies Group. International consensus outcome measures for patients with idiopathic inflammaory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49-54. .
6.
Wiendl H. Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics 2008; 5: 548-557. .
7.
Hengstma GJ, van den Hoogen FH, van Engelen BG. Treatment of the inflammatory myopathies: update and practical recommendations. Exp Opin Pharmacother 2009; 10: 1183-1190. .
8.
Joffe MM, Love LA, Ledf R, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexte and a comparison of their efficacy. Am J Med 1993; 94: 379-387. .
9.
Chwalińska-Sadowska H, Małdykowa H. Polymyositis – dermatomyositis: 25 years of follow-up of 50 patients disease course, treatment, prognostic factors. Mater Med Pol 1990; 22: 213-218. .
10.
Marie I, Hachulla E, Hatron PY, et al. Polymyositis and dermatomyositis: short term and long-term outcome, and predictive factors of prognosis. J Rheumatol 2001; 28: 2230-2237. .
11.
Iorizzo LJ, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008; 59: 99-112. .
12.
Amato AA, Griggs RC. Treatment of idiopathic inflammatory myopathies. Curr Opin Neurol 2003; 16: 569-575. .
13.
Miller J, Walsh Y, Saminaden S, et al. Randomized double blind controlled trial of methotrexate and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci 2002; 199 Suppl. 1: 553. .
14.
Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine A versus metotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000; 29: 95-102. .
15.
Rowin J, Amato AA, Deisher N, et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 2006; 66: 1245-1247. .
16.
Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistent polymyositis and dermatomyositis. Mol Rheumatol 2008; 18: 34-44. .
17.
Bronner IM, Van der Meulen ME, De Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 2006; 65: 1456-1461. .
18.
Kucharz EJ. Zapalenie mięśni z ciałkami wtrętowymi. Pol Arch Med Wewn 1998; 100: 262-266. .
19.
Kucharz EJ. Dziedziczna miopatia z ciałkami wtrętowymi. Przegl Lek 1999; 56: 735-738. .
20.
Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-713. .
21.
Griggs RC. The current status of treatment for inclusion-body myositis. Neurology 2006; 66 Suppl: S30-S32. .
22.
Varjú C, Pethö E, Kutas R, et al. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 2003; 17: 83-87. .
23.
Chung YL, Alexanderson H, Pipitone N, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2007; 57: 694-702.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
